Miraculins Inc. (Miraculins) is a Canada-based medical device company. The Company is engaged in developing non-invasive diagnostic tests and risk assessment technologies. The Company's lead technology program is in the early commercialization phase in the area of diabetes risk assessment. The diabetes program is focused on the Scout DS Non Invasive Diabetes Screening Test, a non-invasive diabetes screening system designed to provide a method for diabetes screening based on diabetes related biomarkers present in the skin. Miraculins' other technology related to cardiovascular disease is focused on the PreVu Non Invasive Skin Cholesterol Point of Care (POC) Test, a non-invasive tool to assist with the risk assessment of coronary artery disease (CAD). The PreVu technology also has a lab processed format called the PreVu Non Invasive Skin Cholesterol Lab Processed (LP) Test. Miraculins' preeclampsia technology is based on a range of protein biomarkers.